nach oben

Die Innere Medizin

Erschienen in:

01.04.2004 | Arzneimitteltherapie

Therapie viraler Atemwegsinfekte

Wirkprinzipien, Strategien und Ausblicke

verfasst von: Dr. G. Rohde, G. Schultze-Werninghaus, T. T. Bauer

Erschienen in: Die Innere Medizin | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Zusammenfassung

Virale Atemwegsinfektionen stellen die größte infektiöse Einzelursache für pulmonale Morbidität dar. Berufliche Ausfallzeiten und daraus folgende Krankenhausaufenthalte tragen erheblich zu den Kosten der Gesundheitsfürsorge bei. Rhinoviren, Influenzavirus A und B, Adenoviren, Parainfluenza, RSV und Coronaviren sind die häufigsten auslösenden Agenzien in diesem Zusammenhang. Trotz dieser enormen Bedeutung ist eine Therapie der virusbedingten Atemwegsinfektionen nur in einem geringen Teil der Infektionen möglich. Einen erheblichen Fortschritt in diesem Zusammenhang hat die Einführung der Neuraminidaseinhibitoren gebracht, die zumindest mit einer Verkürzung der Symptomdauer bei Influenza assoziiert sind. Unter den zur Zeit verfügbaren antiviral wirksamen Substanzen, stellen die Neuraminidasehemmer jedoch nur einen kleinen Teil dar. Im vorliegenden Artikel werden daher die aktuell oder in Kürze verfügbaren Substanzen mit ihrem Wirkmechanismus und dem Stand der klinischen Forschung dargestellt.

Denny FW (1995) The clinical impact of human respiratory virus infections. Am J Respir Crit Care Med 152: S4–12PubMed

Adams PF, Herdershot GE, Marano MA (1999) Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 10

Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003) The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 163: 487–494CrossRefPubMed

Johnston SL (1995) Natural and experimental rhinovirus infections of the lower respiratory tract. Am J Respir Crit Care Med 152: S46–S52PubMed

Rohde G, Wiethege A, Borg I et al. (2003) Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization—a case-control study. Thorax 58: 37–42CrossRefPubMed

Seemungal T, Harper-Owen R, Bhowmik A et al. (2001) Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 1618–1623PubMed

Seemungal TAR, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA (2000) Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 16: 677–683CrossRefPubMed

Jefferson TO, Tyrrell D (2003) Antivirals for the common cold. Cochrane Rev 3rd edn.

Higgins PG, Barrow GI, Galbraith AW, Frost H, Tyrrell DA (1989) A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers. Antiviral Res 12: 49–52CrossRefPubMed

10.

Gwaltney JM (1992) Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 166: 776–782PubMed

11.

Kuzmov K, Galabov AS, Radeva K, Kozhukharova M, Milanov K (1985) Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases. Z Mikrobiol Epidemiol Immunobiol 26–30

12.

Kahlich R, Klima J, Cihla F et al. (1979) Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 23: 11–24PubMed

13.

Rotbart HA (2000) Pleconaril treatment of enterovirus and rhinovirus infections. Infect Med 17: 488–494

14.

Kearns GL, Abdel-Rahman SM, James LP et al. and the Pediatric Pharmacology Research Unit Network (1999) Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Agents Chemother 43: 634–638PubMed

15.

Schiff GM, Sherwood JR (2000) Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 181: 20–26CrossRefPubMed

16.

Rogers JM, Diana GD, McKinlay MA (1999) Pleconaril. A broad spectrum antipicornaviral agent. Adv Exp Med Biol 458: 69–76PubMed

17.

Pevear DC, Tull TM, Seipel ME, Groarke JM (1999) Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43: 2109–2115PubMed

18.

Hayden FG, Herrington DT, Coats TL et al. (2003) Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 36: 1523–1532CrossRefPubMed

19.

McKinlay MA (2001) Recent advances in the treatment of rhinovirus infections. Curr Opin Pharmacol 1: 477–481CrossRefPubMed

20.

Turner RB, Wecker MT, Pohl G et al. (1999) Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 281: 1797–1804CrossRefPubMed

21.

Anzueto A, Niederman MS (2003) Diagnosis and treatment of rhinovirus respiratory infections. Chest 123: 1664CrossRefPubMed

22.

Togo Y, Hornick RB, Felitti VJ et al. (1970) Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA 211: 1149–1156CrossRefPubMed

23.

Wingfield WL, Pollack D, Grunert RR (1969) Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281: 579–584PubMed

24.

Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S (1991) Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 35: 1741–1747PubMed

25.

Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19: 410–417CrossRefPubMed

26.

Lalezari J, Campion K, Keene O, Silagy C (2001) Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 161: 212–217CrossRefPubMed

27.

Makela MJ, Pauksens K, Rostila T et al. (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40: 42–48PubMed

28.

The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group (1998) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352: 1877–1881PubMed

29.

Griffin AD, Perry AS, Fleming DM (2001) Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 19: 293–301PubMed

30.

Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 282: 31–35PubMed

31.

Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M (2001) Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322: 577–579CrossRefPubMed

32.

Hayden FG, Atmar RL, Schilling M et al. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341: 1336–1343PubMed

33.

Nicholson KG, Aoki FY, Osterhaus AD et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845–1850PubMed

34.

Whitley RJ, Hayden FG, Reisinger KS et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127–133CrossRefPubMed

35.

Hayden FG, Treanor JJ, Fritz RS et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240–1246PubMed

36.

Peters PH, Gravenstein S, Norwood P et al. (2001) Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 49: 1025–1031CrossRefPubMed

37.

Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326: 1235CrossRefPubMed

38.

Stiver G (2003) The treatment of influenza with antiviral drugs. Can Med Assoc J 168: 49–56

39.

Edwards KM, Thompson J, Paolini J, Wright PF (1985) Adenovirus infections in young children. Pediatrics 76: 420–424PubMed

40.

Fox JP, Hall Ce, Cooney MK (1977) The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 105: 362–386PubMed

41.

Hierholzer JC (1992) Adenoviruses in the immunocompromised host. Clin Microbiol Rev 5: 262–274PubMed

42.

Gavin PJ, Katz BZ (2002) Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 110: e9PubMed

43.

Ribaud P, Scieux D, Freymuth F, Morinet F, Gluckman E (1999) Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 28: 690–691PubMed

44.

Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705–706PubMed

45.

Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A (2001) Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 32: 1290–1297CrossRefPubMed

46.

Sherman DS, Fish DN (1999) Cidofovir. AIDS Read 9: 215–220PubMed

47.

Simoes EAF (1999) Respiratory syncytial virus infection. Lancet 354: 847–852PubMed

48.

Black CP (2003) Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 48: 209–231PubMed

49.

Taber LH, Knight V, Gilbert BE et al. (1983) Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72: 613–618PubMed

50.

Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC (1985) Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 254: 3047–3051CrossRefPubMed

51.

Smith DW, Frankel LR, Mathers LH et al. (1991) A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 325: 24–29PubMed

52.

Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW (1994) Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 22: 566–572PubMed

53.

Law BJ, Wang EE, MacDonald N et al. (1997) Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 99: E7

54.

Johnson S, Oliver C, Prince GA et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215–1224PubMed

55.

The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531–537

56.

Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA (1999) Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104: 419–427PubMed

57.

Rotbart HA, Hayden FG (2000) Picornavirus infections: a primer for the practitioner. Arch Fam Med 9: 913–920CrossRefPubMed

58.

Castellano F, Mautone G (2002) Decongestant activity of a new formulation of xylometazoline nasal spray: a double-blind, randomized versus placebo and reference drugs controlled, dose-effect study. Drugs Exp Clin Res 28: 27–35PubMed

59.

Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V (1975) Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA 231: 1248–1251CrossRefPubMed

60.

Koytchev R, Vlahov V, Bacratcheva N et al. (2003) Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. Int J Clin Pharmacol Ther 41: 114–125PubMed

61.

McElroy BH, Miller SP (2002) Effectiveness of zinc gluconate glycine lozenges (Cold-Eeze) against the common cold in school-aged subjects: a retrospective chart review. Am J Ther 9: 472–475CrossRefPubMed

62.

Van Straten M, Josling P (2002) Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. Adv Ther 19: 151–159PubMed

63.

Pitkäranta A, Hayden FG (1998) What’s new with common colds? Complications and management. Infect Med 15: 117–128

64.

Gadomski AM (1993) Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections. Pediatr Infect Dis J 12: 115–120PubMed

65.

Zetkin M, Schaldach H (1999) Lexikon der Medizin, 16. Aufl. Ullstein Medical, München

Titel: Therapie viraler Atemwegsinfekte
Wirkprinzipien, Strategien und Ausblicke
verfasst von: Dr. G. Rohde
G. Schultze-Werninghaus
T. T. Bauer
Publikationsdatum: 01.04.2004
Verlag: Springer-Verlag
Erschienen in: Die Innere Medizin / Ausgabe 4/2004
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-003-1111-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Therapie viraler Atemwegsinfekte

Wirkprinzipien, Strategien und Ausblicke

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Das Kompetenznetzwerk „Ambulant erworbene Pneumonie“ (CAPNETZ)

Kompetenznetz Hepatitis (Hep-Net)

Kompetenznetz Entzündlich-Rheumatische Erkrankungen

66-jährige Patientin mit Herzrasen und Synkope

Der „fehlerhafte“ Laborbefund

Schmerztherapie bei chronischer Pankreatitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin